01—Abstract
Summary
Summary of the 8-K filed May 21, 2026. Cited figures are marked; the original filing is the authoritative source.
Quest Diagnostics Inc. (DGX) filed an 8-K report on May 21, 2026, detailing the results of its 2026 Annual Meeting of Stockholders held on May 20, 2026.
The primary focus of this filing is the voting outcomes on key corporate governance matters, including director elections and executive compensation. The company saw overwhelming support for its nominated directors, with all nominees being re-elected with substantial 'For' votes, indicating strong shareholder confidence in the current board leadership. Furthermore, shareholders approved the executive compensation as disclosed in the 2026 Proxy Statement through an advisory resolution, and also ratified the appointment of PricewaterhouseCoopers as the independent registered public accounting firm for the fiscal year 2026.
Notably, a stockholder proposal advocating for an independent board chairman was not approved, reflecting a preference for the current board structure. Overall, the results signal a positive shareholder sentiment regarding the company's governance and financial oversight.
02—Key points
Key Highlights
- All director nominees were re-elected to the board with substantial majority support.
- The advisory resolution to approve executive officer compensation received strong approval from shareholders.
- PricewaterhouseCoopers was ratified as the independent registered public accounting firm for 2026.
- A significant number of non-votes were recorded across most director elections and other proposals.
- A stockholder proposal for an independent board chairman was not approved, indicating shareholder preference against this change.
- Voting results for all proposals demonstrate a high level of shareholder engagement and alignment with management's recommendations.
03—Questions
Frequently Asked Questions
Were all of Quest Diagnostics' director nominees elected?
Yes, all director nominees presented at the 2026 Annual Meeting of Stockholders were elected for terms expiring at the 2027 Annual Meeting. Each nominee received a significant majority of 'For' votes.
Did shareholders approve the executive compensation plan?
Yes, the advisory resolution to approve the executive officer compensation disclosed in the Company’s 2026 Proxy Statement was approved by shareholders.
Who is Quest Diagnostics' auditor for 2026, and was their appointment ratified?
PricewaterhouseCoopers has been ratified as Quest Diagnostics' independent registered public accounting firm for 2026. The ratification received strong approval from shareholders.
What was the outcome of the stockholder proposal regarding an independent board chairman?
The stockholder proposal requesting an independent board chairman was not approved by the shareholders. The 'Against' votes significantly outnumbered the 'For' votes.
04—Continue